Phylogica and Isogenica: Strategic alliance fast tracking screening of drug discovery targets
Phylogica Ltd and Isogenica Ltd have succeeded in a proof of concept project demonstrating compatibility of Isogenica’s proprietary CIS in-vitro display technology for peptide engineering and drug discovery with Phylogica’s Phylomer drug discovery platform.
Phylogica scientists are now confident that using the display technology will ensure accelerated screening of the company’s vast Phylomer libraries to meet demand from potential pharmaceutical partners. Isogenica has been successful in hitting all milestones to date related to the collaboration, which was announced in January 2010.
The objectives of the project were to use Isogenica’s CIS display to achieve further optimisation of Phylogica’s lead compounds targeting CD40 ligand (CD40L).
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

How do our cells respond to stress? - Molecular biologists reverse-engineer a complex cellular structure that is associated with neurodegenerative diseases such as ALS
Affitech signs license agreement for single-chain antibody technology with Micromet

99 million people included in largest global COVID-19 vaccine safety study - Global Vaccine Data Network utilises vast data sets to detect potential vaccine safety signals
Affibody AB provides novel molecular imaging agents for visualizing HER2-expressing cancer
BTG signs agreement with Novacea and KuDOS for AQ4N
To-BBB awarded EUR 1.25 million European FP7 funding to develop treatments for inherited retinal diseases
Galapagos enters into discovery collaboration with Idenix for infectious disease programs
Bayer and Ortho-McNeil, Inc. Outline Phase III Study Program of Oral Factor Xa Inhibitor Rivaroxaban in Chronic Indications - Patient Recruitment for Phase III Clinical Trial to Start in Studies of Oral Anticoagulant in Chronic Indications
AnaSpec and UW TechTransfer Sign Licensing Agreement for Protein Tyrosine Phosphatases
